Congenital hypogonadotropic hypogonadism;Hypogonadisme hypogonadotrope congénital

Annales d'Endocrinologie

Volumn 70, Issue 1, 2009, Pages 2-13

  Roze, C ^a   Touraine, P ^a,b   Leger, J ^a   de Roux, N ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

FGFR1; GNRHR; GPR54; Hypogonadotropic hypogonadism; KAL1; Prok2; ProKR2

Indexed keywords

ANDROGEN; ESTRADIOL; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FOLLITROPIN; G PROTEIN COUPLED RECEPTOR 54; GESTAGEN; GONADORELIN; GONADOTROPIN; LEPTIN; LUTEINIZING HORMONE; NUCLEAR RECEPTOR DAX 1; TESTOSTERONE; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR HESX1; TRANSCRIPTION FACTOR LHX3; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX3;

ANDROGEN THERAPY; BARDET BIEDL SYNDROME; CELL MIGRATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE TRANSMISSION; FOLLITROPIN RELEASE; GENETIC COUNSELING; GENETIC DISORDER; HORMONE SUBSTITUTION; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFERTILITY; LUTEINIZING HORMONE RELEASE; MICROPENIS; NERVE CELL; PERINATAL DEVELOPMENT; PRADER WILLI SYNDROME; PRENATAL DIAGNOSIS; PREVALENCE; RISK FACTOR; SHORT SURVEY; SYNDROME CHARGE;

DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGONADISM; INCIDENCE; INFANT, NEWBORN; LUTEINIZING HORMONE; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; SYNDROME;

EID: 61349190941     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2008.06.005     Document Type: Short Survey

References (82)

1. Lee P.A., Mazur T., Danish R., Amrhein J., Blizzard R.M., Money J., et al. Micropenis. I. Criteria, etiologies and classification. Johns Hopkins Med J 146 (1980) 156-163
2. Sedlmeyer I.L., and Palmert M.R. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab 87 (2002) 1613-1620
3. Feldman K.W., and Smith D.W. Fetal phallic growth and penile standards for newborn male infants. J Pediatr 86 (1975) 395-398
4. Seminara S.B., Hayes F.J., and Crowley Jr. W.F. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Endocr Rev 19 (1998) 521-539
5. Grumbach M.M. A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. J Clin Endocrinol Metab 90 (2005) 3122-3127
6. In: Tanner J. (Ed). Growth at adolescence (1978), Blackwell Scientific, Oxford
7. Main K.M., Schmidt I.M., and Skakkebaek N.E. A possible role for reproductive hormones in newborn boys: progressive hypogonadism without the postnatal testosterone peak. J Clin Endocrinol Metab 85 (2000) 4905-4907
8. Delemarre-van de Waal H.A. Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism-diagnostic and therapeutic aspects. Eur J Endocrinol 151 Suppl. 3 (2004) U89-U94
9. Degros V., Cortet-Rudelli C., Soudan B., and Dewailly D. The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism from constitutional delayed puberty. Eur J Endocrinol 149 (2003) 23-29
10. Young J., Chanson P., Salenave S., Noel M., Brailly S., O'Flaherty M., et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 90 (2005) 724-728
11. Garel C., and Leger J. Contribution of magnetic resonance imaging in non-tumoral hypopituitarism in children. Horm Res 67 (2006) 194-202
12. Darby E., and Anawalt B.D. Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol 4 (2005) 293-309
13. Schwanzel-Fukuda M., Bick D., and Pfaff D.W. Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Brain Res Mol Brain Res 6 (1989) 311-326
14. Legouis R., Hardelin J.P., Levilliers J., Claverie J.M., Compain S., Wunderle V., et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 67 (1991) 423-435
15. Soussi-Yanicostas N., de Castro F., Julliard A.K., Perfettini I., Chedotal A., and Petit C. Anosmin-1, defective in the X-linked form of Kallmann syndrome, promotes axonal branch formation from olfactory bulb output neurons. Cell 109 (2002) 217-228
16. Hardelin J.P., Julliard A.K., Moniot B., Soussi-Yanicostas N., Verney C., Schwanzel-Fukuda M., et al. Anosmin-1 is a regionally restricted component of basement membranes and interstitial matrices during organogenesis: implications for the developmental anomalies of X chromosome-linked Kallmann syndrome. Dev Dyn 215 (1999) 26-44
17. Massin N., Pecheux C., Eloit C., Bensimon J.L., Galey J., Kuttenn F., et al. X chromosome-linked Kallmann syndrome: clinical heterogeneity in three siblings carrying an intragenic deletion of the KAL-1 gene. J Clin Endocrinol Metab 88 (2003) 2003-2008
18. Dode C., Levilliers J., Dupont J.M., De Paepe A., Le Du N., Soussi-Yanicostas N., et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 33 (2003) 463-465
19. Albuisson J., Pecheux C., Carel J.C., Lacombe D., Leheup B., Lapuzina P., et al. Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum Mutat 25 (2005) 98-99
20. Pitteloud N., Acierno Jr. J.S., Meysing A., Eliseenkova A.V., Ma J., Ibrahimi O.A., et al. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 103 (2006) 6281-6286
21. Sato N., Katsumata N., Kagami M., Hasegawa T., Hori N., Kawakita S., et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 89 (2004) 1079-1088
22. Zenaty D., Bretones P., Lambe C., Guemas I., David M., Leger J., et al. Paediatric phenotype of Kallmann syndrome due to mutations of fibroblast growth factor receptor 1 (FGFR1). Mol Cell Endocrinol 254-255 (2006) 78-83
23. Dode C., Teixeira L., Levilliers J., Fouveaut C., Bouchard P., Kottler M.L., et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2 (2006) e175
24. Pitteloud N., Zhang C., Pignatelli D., Li J.D., Raivio T., Cole L.W., et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 104 (2007) 17447-17452
25. Ng K.L., Li J.D., Cheng M.Y., Leslie F.M., Lee A.G., and Zhou Q.Y. Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. Science 308 (2005) 1923-1927
26. Prosser H.M., Bradley A., Chesham J.E., Ebling F.J., Hastings M.H., and Maywood E.S. Prokineticin receptor 2 (ProKR2) is essential for the regulation of circadian behavior by the suprachiasmatic nuclei. Proc Natl Acad Sci USA 104 (2007) 648-653
27. Miura K., Acierno Jr. J.S., and Seminara S.B. Characterization of the human nasal embryonic LHRH factor gene, NELF, and a mutation screening among 65 patients with idiopathic hypogonadotropic hypogonadism (IHH). J Hum Genet 49 (2004) 265-268
28. Salenave S., Chanson P., Bry H., Pugeat M., Cabrol S., Carel J.C., et al. Kallmann's Syndrome: a comparison of the reproductive phenotypes in men carrying KAL1 and FGFR1/KAL2 mutations. J Clin Endocrinol Metab 93 (2008) 758-763
29. Achermann J.C., Ozisik G., Meeks J.J., and Jameson J.L. Genetic causes of human reproductive disease. J Clin Endocrinol Metab 87 (2002) 2447-2454
30. Wu W., Cogan J.D., Pfaffle R.W., Dasen J.S., Frisch H., O'Connell S.M., et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 18 (1998) 147-149
31. Netchine I., Sobrier M.L., Krude H., Schnabel D., Maghnie M., Marcos E., et al. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 25 (2000) 182-186
32. Reynaud R., Gueydan M., Saveanu A., Vallette-Kasic S., Enjalbert A., Brue T., et al. Genetic screening of combined pituitary hormone deficiency: experience in 195 patients. J Clin Endocrinol Metab 91 (2006) 3329-3336
33. Kelberman D., Rizzoti K., Avilion A., Bitner-Glindzicz M., Cianfarani S., Collins J., et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 116 (2006) 2442-2455
34. Reynaud R., Barlier A., Vallette-Kasic S., Saveanu A., Guillet M.P., Simonin G., et al. An uncommon phenotype with familial central hypogonadism caused by a novel PROP1 gene mutant truncated in the transactivation domain. J Clin Endocrinol Metab 90 (2005) 4880-4887
35. Machinis K., Pantel J., Netchine I., Leger J., Camand O.J., Sobrier M.L., et al. Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 69 (2001) 961-968
36. Tajima T., Hattori T., Nakajima T., Okuhara K., Tsubaki J., and Fujieda K. A novel missense mutation (P366T) of the LHX4 gene causes severe combined pituitary hormone deficiency with pituitary hypoplasia, ectopic posterior lobe and a poorly developed sella turcica. Endocr J 54 (2007) 637-641
37. Pfaeffle R.W., Hunter C.S., Savage J.J., Duran-Prado M., Mullen R.D., Neeb Z.P., et al. Three novel missense mutations within the LHX4 gene are associated with variable pituitary hormone deficiencies. J Clin Endocrinol Metab (2007)
38. Dattani M.T., Martinez-Barbera J.P., Thomas P.Q., Brickman J.M., Gupta R., Martensson I.L., et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 19 (1998) 125-133
39. Sobrier M.L., Netchine I., Heinrichs C., Thibaud N., Vie-Luton M.P., Van Vliet G., et al. Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary. Hum Mutat 25 (2005) 503
40. Sobrier M.L., Maghnie M., Vie-Luton M.P., Secco A., di Iorgi N., Lorini R., et al. Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities. J Clin Endocrinol Metab 91 (2006) 4528-4536
41. Sato N., Kamachi Y., Kondoh H., Shima Y., Morohashi K., Horikawa R., et al. Hypogonadotropic hypogonadism in an adult female with a heterozygous hypomorphic mutation of SOX2. Eur J Endocrinol 156 (2007) 167-171
42. Lachlan K.L., Collinson M.N., Sandford R.O., van Zyl B., Jacobs P.A., and Thomas N.S. Functional disomy resulting from duplications of distal Xq in four unrelated patients. Hum Genet 115 (2004) 399-408
43. Woods K.S., Cundall M., Turton J., Rizotti K., Mehta A., Palmer R., et al. Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 76 (2005) 833-849
44. Roessler E., Ermilov A.N., Grange D.K., Wang A., Grachtchouk M., Dlugosz A.A., et al. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum Mol Genet 14 (2005) 2181-2188
45. Bo-Abbas Y., Acierno Jr. J.S., Shagoury J.K., Crowley Jr. W.F., and Seminara S.B. Autosomal recessive idiopathic hypogonadotropic hypogonadism: genetic analysis excludes mutations in the gonadotropin-releasing hormone (GnRH) and GnRH receptor genes. J Clin Endocrinol Metab 88 (2003) 2730-2737
46. de Roux N., Young J., Misrahi M., Genet R., Chanson P., Schaison G., et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 337 (1997) 1597-1602
47. Bhagavath B., Ozata M., Ozdemir I.C., Bolu E., Bick D.P., Sherins R.J., et al. The prevalence of gonadotropin-releasing hormone receptor mutations in a large cohort of patients with hypogonadotropic hypogonadism. Fertil Steril 84 (2005) 951-957
48. Karges B., Karges W., and de Roux N. Clinical and molecular genetics of the human GnRH receptor. Hum Reprod Update 9 (2003) 523-530
49. de Roux N., Young J., Brailly-Tabard S., Misrahi M., Milgrom E., and Schaison G. The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. J Clin Endocrinol Metab 84 (1999) 567-572
50. de Roux N., Genin E., Carel J.C., Matsuda F., Chaussain J.L., and Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 100 (2003) 10972-10976
51. Smith J.T., Clifton D.K., and Steiner R.A. Regulation of the neuroendocrine reproductive axis by kisspeptin-GPR54 signaling. Reproduction 131 (2006) 623-630
52. Lanfranco F., Gromoll J., von Eckardstein S., Herding E.M., Nieschlag E., and Simoni M. Role of sequence variations of the GnRH receptor and G protein-coupled receptor 54 gene in male idiopathic hypogonadotropic hypogonadism. Eur J Endocrinol 153 (2005) 845-852
53. Seminara S.B., Messager S., Chatzidaki E.E., Thresher R.R., Acierno Jr. J.S., Shagoury J.K., et al. The GPR54 gene as a regulator of puberty. N Engl J Med 349 (2003) 1614-1627
54. Semple R.K., Achermann J.C., Ellery J., Farooqi I.S., Karet F.E., Stanhope R.G., et al. Two novel missense mutations in g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 90 (2005) 1849-1855
55. Tenenbaum-Rakover Y., Commenges-Ducos M., Iovane A., Aumas C., Admoni O., and de Roux N. Neuroendocrine phenotype analysis in five patients with isolated hypogonadotropic hypogonadism due to a L102P inactivating mutation of GPR54. J Clin Endocrinol Metab 92 (2007) 1137-1144
56. Phillip M., Arbelle J.E., Segev Y., and Parvari R. Male hypogonadism due to a mutation in the gene for the beta-subunit of follicle-stimulating hormone. N Engl J Med 338 (1998) 1729-1732
57. Layman L.C., Lee E.J., Peak D.B., Namnoum A.B., Vu K.V., van Lingen B.L., et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. N Engl J Med 337 (1997) 607-611
58. Layman L.C., Porto A.L., Xie J., da Motta L.A., da Motta L.D., Weiser W., et al. FSH beta gene mutations in a female with partial breast development and a male sibling with normal puberty and azoospermia. J Clin Endocrinol Metab 87 (2002) 3702-3707
59. Weiss J., Axelrod L., Whitcomb R.W., Harris P.E., Crowley W.F., and Jameson J.L. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med 326 (1992) 179-183
60. Matthews C.H., Borgato S., Beck-Peccoz P., Adams M., Tone Y., Gambino G., et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet 5 (1993) 83-86
61. Valdes-Socin H., Salvi R., Daly A.F., Gaillard R.C., Quatresooz P., Tebeu P.M., et al. Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene. N Engl J Med 351 (2004) 2619-2625
62. Lofrano-Porto A., Barra G.B., Giacomini L.A., Nascimento P.P., Latronico A.C., Casulari L.A., et al. Luteinizing hormone beta mutation and hypogonadism in men and women. N Engl J Med 357 (2007) 897-904
63. Salvi R., Gomez F., Fiaux M., Schorderet D., Jameson J.L., Achermann J.C., et al. Progressive onset of adrenal insufficiency and hypogonadism of pituitary origin caused by a complex genetic rearrangement within DAX-1. J Clin Endocrinol Metab 87 (2002) 4094-4100
64. Achermann J.C., Gu W.X., Kotlar T.J., Meeks J.J., Sabacan L.P., Seminara S.B., et al. Mutational analysis of DAX1 in patients with hypogonadotropic hypogonadism or pubertal delay. J Clin Endocrinol Metab 84 (1999) 4497-4500
65. Tabarin A., Achermann J.C., Recan D., Bex V., Bertagna X., Christin-Maitre S., et al. A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 105 (2000) 321-328
66. Mantovani G., Ozisik G., Achermann J.C., Romoli R., Borretta G., Persani L., et al. Hypogonadotropic hypogonadism as a presenting feature of late-onset X-linked adrenal hypoplasia congenita. J Clin Endocrinol Metab 87 (2002) 44-48
67. Ozata M., Ozdemir I.C., and Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 84 (1999) 3686-3695
68. Clement K., Vaisse C., Lahlou N., Cabrol S., Pelloux V., Cassuto D., et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 (1998) 398-401
69. Farooqi I.S., Wangensteen T., Collins S., Kimber W., Matarese G., Keogh J.M., et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 356 (2007) 237-247
70. Jackson R.S., Creemers J.W., Ohagi S., Raffin-Sanson M.L., Sanders L., Montague C.T., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16 (1997) 303-306
71. Burman P., Ritzen E.M., and Lindgren A.C. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 22 (2001) 787-799
72. Green J.S., Parfrey P.S., Harnett J.D., Farid N.R., Cramer B.C., Johnson G., et al. The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. N Engl J Med 321 (1989) 1002-1009
73. Katsanis N. The oligogenic properties of Bardet-Biedl syndrome. Hum Mol Genet 13 Special number 1 (2004) R65-R71
74. Sanlaville D., and Verloes A. Charge syndrome: an update. Eur J Hum Genet (2007)
75. Pinto G., Abadie V., Mesnage R., Blustajn J., Cabrol S., Amiel J., et al. Charge syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. J Clin Endocrinol Metab 90 (2005) 5621-5626
76. Velasquez-Urzola A., Leger J., Aigrain Y., and Czernichow P. Hypoplasia of the penis: etiologic diagnosis and results of treatment with delayed-action testosterone. Arch Pediatr 5 (1998) 844-850
77. Piippo S., Lenko H., Kainulainen P., and Sipila I. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. J Clin Endocrinol Metab 89 (2004) 3241-3247
78. Ankarberg-Lindgren C., Elfving M., Wikland K.A., and Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab 86 (2001) 3039-3044
79. Hoffman A.R., and Crowley Jr. W.F. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 307 (1982) 1237-1241
80. Pitteloud N., Hayes F.J., Dwyer A., Boepple P.A., Lee H., and Crowley Jr. W.F. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 87 (2002) 4128-4136
81. Main K.M., Schmidt I.M., Toppari J., and Skakkebaek N.E. Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH. Eur J Endocrinol 146 (2002) 75-79
82. Pitteloud N., Quinton R., Pearce S., Raivio T., Acierno J., Dwyer A., et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 117 (2007) 457-463